ArticleQuantitative imaging in medicine and surgery2026
Cardiac magnetic resonance assessment of long-term cardiac function after early recombinant staphylokinase thrombolysis before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction patients.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The long-term effects of early thrombolytic therapy administered within 120 minutes of the first medical contact and before primary percutaneous coronary intervention (PCI) on left ventricular (LV) and left atrial (LA) function in ST-segment elevation myocardial infarction (STEMI) patients remain unknown. This study aimed to explore the long-term effects of early recombinant staphylokinase (r-SAK) thrombolysis administered up to 120 minutes before primary PCI on the LV and LA function of STEMI patients using cardiac magnetic resonance (CMR) imaging. Methods: This retrospective study analyzed the one-year follow-up CMR imaging data of STEMI patients enrolled in the multi-center, prospective OPTIMA-5 trial, conducted from November 2021 to August 2022. Patients were randomized to receive either a single half-dose of 5 mg r-SAK or normal saline (NS) before primary PCI. LV and LA functional parameters were compared between groups using appropriate statistical tests. Results: A total of 66 patients were included (r-SAK, n=32; NS, n=34). Compared to the NS group, the r-SAK group had a significantly higher cardiac index (2.77 Conclusions: The early administration of r-SAK thrombolysis before primary PCI significantly improves long-term LV and LA function in STEMI patients, suggesting a potential strategy for enhancing cardiac recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.